{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:16:03Z","timestamp":1761664563376,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which leads to severe and repeated bleedings. There is a need to understand the optimal treatment pathway for FVIII inhibitors with the use of immune tolerance induction (ITI) and the role of haemostatic \u2018bypassing\u2019 agents (BPA) on-demand (OD) or prophylactically (Px). The aim of this study was to gain a better understanding of the real-world use of BPA therapy administered prophylactically or on-demand concomitant with ITI, for the treatment of an inhibitor to FVIII replacement therapy in patients with severe haemophilia A.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective observational data were used to capture disease management information for patients who were aged 16 or under and had received ITI and BPA treatment for their most recent inhibitor from Jan-2015 to Jan-2019, for 47 patients in the UK and Germany. Descriptive comparisons of the clinical effectiveness and resource utilisation of Px and OD BPA therapy during ITI were conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During ITI and BPA treatment, for an inhibitor, bleeding events averaged 1.5 and 1.2 for Px and OD treatment respectively. Compared to only BPA therapy we see 3.4 and 1.4 bleeding events for Px and OD respectively during an inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Baseline disease characteristics differed between BPA therapy cohorts and this resulted in higher clinical effectiveness of ITI treatment alongside BPA Px than BPA OD during an inhibitor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02654-0","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:03:53Z","timestamp":1678187033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review"],"prefix":"10.1186","volume":"18","author":[{"given":"George","family":"Morgan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-8331","authenticated-orcid":false,"given":"Emily","family":"Back","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Finnegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"issue":"1","key":"2654_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.16377","volume":"189","author":"M Cormier","year":"2020","unstructured":"Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol. 2020;189(1):39\u201353. https:\/\/doi.org\/10.1111\/bjh.16377.","journal-title":"Br J Haematol"},{"issue":"3","key":"2654_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/rth2.12314","volume":"4","author":"F Kloosterman","year":"2020","unstructured":"Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G, Fijnvandraat K. Hemophilia management: huge impact of a tiny difference. Res Pract Thromb Haemost. 2020;4(3):377\u201385. https:\/\/doi.org\/10.1002\/rth2.12314.","journal-title":"Res Pract Thromb Haemost"},{"key":"2654_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/BTT.S252580","volume":"15","author":"E Marchesini","year":"2021","unstructured":"Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: a review. Biologics. 2021;15:221\u201335. https:\/\/doi.org\/10.2147\/BTT.S252580.","journal-title":"Biologics"},{"issue":"4","key":"2654_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","volume":"9","author":"J Wight","year":"2003","unstructured":"Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418\u201335. https:\/\/doi.org\/10.1046\/j.1365-2516.2003.00780.x.","journal-title":"Haemophilia"},{"issue":"219","key":"2654_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0800-z","volume":"15","author":"PLF Giangrande","year":"2020","unstructured":"Giangrande PLF, Hermans C, O\u2019Mahony B, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis. 2020;15(219):1\u20136. https:\/\/doi.org\/10.1186\/s13023-018-0800-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2654_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/hae.14167","volume":"27","author":"V Jim\u00e9nez-Yuste","year":"2021","unstructured":"Jim\u00e9nez-Yuste V, Auerswald G, Benson G, et al. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia. 2021;27(3):340\u201350. https:\/\/doi.org\/10.1111\/hae.14167.","journal-title":"Haemophilia"},{"issue":"10","key":"2654_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.28474","volume":"67","author":"J Oldenburg","year":"2020","unstructured":"Oldenburg J, Shima M, Kruse-Jarres R, et al. Outcomes in children with hemophilia A with inhibitors: results from a noninterventional study. Pediatr Blood Cancer. 2020;67(10):1\u201310. https:\/\/doi.org\/10.1002\/pbc.28474.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2654_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5395\/RDE.2017.42.2.152","volume":"42","author":"HY Kim","year":"2017","unstructured":"Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher\u2019s exact test. Restor Dent Endod. 2017;42(2):152. https:\/\/doi.org\/10.5395\/RDE.2017.42.2.152.","journal-title":"Restor Dent Endod"},{"key":"2654_CR9","unstructured":"StataCorp. Stata Statistical Software: Release 17. Published online 2021."},{"issue":"18","key":"2654_CR10","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1056\/NEJMOA1104435","volume":"365","author":"C Leissinger","year":"2011","unstructured":"Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684\u201392. https:\/\/doi.org\/10.1056\/NEJMOA1104435.","journal-title":"N Engl J Med"},{"issue":"4","key":"2654_CR11","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/hae.13534","volume":"24","author":"SL Carpenter","year":"2018","unstructured":"Carpenter SL, Khair K, Gringeri A, Valentino LA. Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII. Haemophilia. 2018;24(4):570\u20137. https:\/\/doi.org\/10.1111\/hae.13534.","journal-title":"Haemophilia"},{"issue":"5","key":"2654_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/HAE.12181","volume":"19","author":"T Livnat","year":"2013","unstructured":"Livnat T, Martinowitz U, Azar-Avivi S, et al. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors: a thrombin generation-guided pilot study. Haemophilia. 2013;19(5):782\u20139. https:\/\/doi.org\/10.1111\/HAE.12181.","journal-title":"Haemophilia"},{"issue":"4","key":"2654_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/J.1365-2141.2010.08378.X","volume":"151","author":"J Klintman","year":"2010","unstructured":"Klintman J, Astermark J, Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol. 2010;151(4):381\u20136. https:\/\/doi.org\/10.1111\/J.1365-2141.2010.08378.X.","journal-title":"Br J Haematol"},{"issue":"5","key":"2654_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/J.1365-2516.2008.01767.X","volume":"14","author":"J Blatny","year":"2008","unstructured":"Blatny J, Kohlerova S, Zapletal O, Fiamoli V, Penka M, Smith O. Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors. Haemophilia. 2008;14(5):1140\u20132. https:\/\/doi.org\/10.1111\/J.1365-2516.2008.01767.X.","journal-title":"Haemophilia"},{"issue":"8044","key":"2654_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","volume":"2","author":"HH Brackmann","year":"1977","unstructured":"Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet. 1977;2(8044):933. https:\/\/doi.org\/10.1016\/S0140-6736(77)90871-6.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2654_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/J.1423-0410.1996.TB01346.X","volume":"70","author":"HH Brackmann","year":"1996","unstructured":"Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors\u2013twenty years\u2019 \u201cbonn protocol.\u201d Vox Sang. 1996;70(Suppl 1):30\u20135. https:\/\/doi.org\/10.1111\/J.1423-0410.1996.TB01346.X.","journal-title":"Vox Sang"},{"issue":"5","key":"2654_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1046\/J.1365-2516.2003.00791.X","volume":"9","author":"MD Carcao","year":"2003","unstructured":"Carcao MD, Connolly BL, Chait P, et al. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia. 2003;9(5):578\u201383. https:\/\/doi.org\/10.1046\/J.1365-2516.2003.00791.X.","journal-title":"Haemophilia"},{"issue":"4","key":"2654_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/J.1365-2516.2006.01284.X","volume":"12","author":"D DiMichele","year":"2006","unstructured":"DiMichele D, N\u00e9grier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12(4):352\u201362. https:\/\/doi.org\/10.1111\/J.1365-2516.2006.01284.X.","journal-title":"Haemophilia"},{"key":"2654_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2516.2012.02870.X","author":"A Faradji","year":"2012","unstructured":"Faradji A, Lavigne-Lissalde G, Grunebaum L, Desprez D, Feugeas O, Lapalud P. Late immune tolerance induction in an adult with severe haemophilia A and high-responder inhibitor: 1-year outcome. Haemophilia. 2012. https:\/\/doi.org\/10.1111\/J.1365-2516.2012.02870.X.","journal-title":"Haemophilia"},{"issue":"1","key":"2654_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/J.1365-2516.1995.TB00036.X","volume":"1","author":"W Kreuz","year":"1995","unstructured":"Kreuz W, Ehrenforth S, Funk M, et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia. 1995;1(1):24\u201332. https:\/\/doi.org\/10.1111\/J.1365-2516.1995.TB00036.X.","journal-title":"Haemophilia"},{"issue":"3","key":"2654_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/J.1365-2516.2007.01442.X","volume":"13","author":"CA Leissinger","year":"2007","unstructured":"Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007;13(3):249\u201355. https:\/\/doi.org\/10.1111\/J.1365-2516.2007.01442.X.","journal-title":"Haemophilia"},{"issue":"2","key":"2654_CR22","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1111\/HAE.12871","volume":"22","author":"M Sholzberg","year":"2016","unstructured":"Sholzberg M, Floros G, Teitel J. Successful immune tolerance induction with von Willebrand factor containing concentrate in an adult with haemophilia A and chronic inhibitor: a case study. Haemophilia. 2016;22(2):e104\u20136. https:\/\/doi.org\/10.1111\/HAE.12871.","journal-title":"Haemophilia"},{"issue":"January","key":"2654_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02991","volume":"10","author":"S Lacroix-Desmazes","year":"2020","unstructured":"Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating factor VIII: recent progress. Front Immunol. 2020;10(January):1\u201320. https:\/\/doi.org\/10.3389\/fimmu.2019.02991.","journal-title":"Front Immunol"},{"issue":"10","key":"2654_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1055\/s-0040-1714279","volume":"120","author":"G Gelbenegger","year":"2020","unstructured":"Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost. 2020;120(10):1357\u201370. https:\/\/doi.org\/10.1055\/s-0040-1714279.","journal-title":"Thromb Haemost"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02654-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:04:25Z","timestamp":1678187065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02654-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2654"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02654-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval to report this case was obtained from the Research Ethics Sub-committee of the Faculty of Health and Social Care within the University of Chester. Informed consent for patient information to be published in this article was not obtained because the study only accessed patient medical records to collect retrospective data and no personally identifiable data, there will be no way of connecting the data collected with the patients and hence no reason for contact with patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GM, EB, DR and JOH are employees of HCD Economics, and received funding via Investigator-Initiated Research grant (no. IISR-2018-104273) from Baxalta GmbH, an indirect wholly owned subsidiary of Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}